Showing results (181-190 of 453) with videos related to
Sort By:
Pageof 46
Journal for Immunotherapy of Cancer|June 18, 2025
Phase 1 first-in-human dose-escalation study of IMSA101, a novel cyclic di-nucleotide STING agonist, for patients with advanced solid tumor malignanciesJay Jacoby, Deva Mahalingam, Angela Alistar, et al.JAMA Network Open|May 20, 2022
Prevalence of Germline Findings Among Tumors From Cancer Types Lacking Hereditary Testing GuidelinesTimothy A Yap, Arya Ashok, Jessica Stoll, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 14, 2011
Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumorsJohanna C Bendell, Jordi Rodon, Howard A Burris, et al.Investigational New Drugs|March 7, 2020
Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant gliomaAntje Wick, Annick Desjardins, Cristina Suarez, et al.The Oncologist|June 13, 2023
A Phase I Trial of Bevacizumab and Temsirolimus in Combination With Valproic Acid in Advanced Solid TumorsBlessie Elizabeth Nelson, Apostolia M Tsimberidou, Xueyao Fu, et al.Cancer Chemotherapy and Pharmacology|February 28, 2008
Cantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic studyJordi Rodon, Mitchell Garrison, Lisa A Hammond, et al.Cancers|August 12, 2022
Clinical Outcomes of Patients with Recurrent Microsatellite-Stable Endometrial Cancer in Early-Phase Immunotherapy Clinical TrialsJeffrey A How, Amir A Jazaeri, Siqing Fu, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 30, 2013
Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumorsGeoffrey I Shapiro, Jordi Rodon, Cynthia Bedell, et al.The Oncologist|March 17, 2021
Overview of Ocular Side Effects of SelinexorNagham Al-Zubidi, Dan S Gombos, David S Hong, et al.European Journal of Cancer (Oxford, England : 1990)|November 18, 2017
A first-in-human phase I study of SAR125844, a selective MET tyrosine kinase inhibitor, in patients with advanced solid tumours with MET amplificationEric Angevin, Gianluca Spitaleri, Jordi Rodon, et al.Pageof 46